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The objectives of this paper were to evaluate the pharmacokinetics of ganoderic acids A and F after a single oral dose of the water
extract of MG2-strain Ling Zhi (MG2FB-WE) and to assess the inﬂuence of food on the pharmacokinetics in 12 healthy male
volunteers. This study was a single-dose, open-label, randomized, two-phase crossover study with at least 2 wk washout period.
Each subject was randomly assigned to receive a single oral dose of 3,000mg of MG2FB-WE in granular formulation dissolved in
200mL of warm water, either under a fasting condition, or immediately after a standard breakfast (fed condition). Blood samples
were collected immediately before and at speciﬁc time points until 8h after MG2FB-WE administration. Plasma ganoderic acids
A and F concentrations were determined by using liquid chromatography-mass spectrometry (LC-MS) technique. In conclusion,
the pharmacokinetic proﬁle of both ganoderic acids under a fasting condition was characterized by rapid absorption from the
gastrointestinal tract (Tmax at approximately 30min) and a short elimination half-life (<40min). Food signiﬁcantly decreased
Cmax and delayed Tmax, but did not aﬀect the extent of ganoderic acid A absorption. However, concomitant food intake markedly
impeded both rate and extent of ganoderic acid F absorption.
1.Introduction
The fruiting body of Ganoderma lucidum known as Ling
Zhi in China, one of the most famous traditional Chi-
nese medicinal mushroom, has been used extensively for
longevity and health promotion in China and other Asian
countries for thousands of years [1–3]. Although it is still
not clear about Ling Zhi’s mechanism on longevity and
health promotion, Ling Zhi has been used for the prevention
or treatment of various conditions and diseases such as
anorexia, neurasthenia, insomnia, migraine, allergy, asthma,
bronchitis, gastritis, hepatitis, nephritis, arthritis, lupus ery-
thematosus, diabetes, hypertension, hypercholesterolemia,
cardiovascular problems, and cancers [2, 3].
Modern investigations have revealed that Ling Zhi con-
tains a variety of phytochemical compounds. One of the
potentbiologicallyactivecompoundsthathasbeenshownto
possess diverse and potentially signiﬁcant pharmacological
activities is the bitter triterpenes [2]. Since the ﬁrst discovery
of ganoderic acids A and B, more than 150 types of
triterpenes have been isolated from various parts of Ling Zhi
[2, 3], among which ganoderic acids A and F (Figure 1)h a v e
received considerable attention due to their conspicuous
pharmacological properties for example, antihypertensive
[4], antinociceptive [5], antioxidative [6], farnesyl protein
transferase inhibitory [7], and hepatoprotective activities [8,
9], especially anticancer activity [10–13] which is the most
attractive character of this medicinal mushroom. Ganoderic2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Structures of ganoderic acids A and F.
acid A has been reported to suppress growth and invasion of
highlyinvasivehumanbreastcancercellsviadownregulation
of expression of cyclin-dependent kinase 4 that regulates cell
cycle G1 phase progression, and via suppression of secretion
of urokinase-type plasminogen activator that implicates in
tumor cell invasion and metastasis [12]. On the other hand,
ganoderic acid F has exhibited antitumor and antimetastatic
activities through inhibition of angiogenesis [10]a n da l t e r -
ation of proteins involving cell proliferation and/or cell
death,carcinogenesis,oxidativestress,calciumsignaling,and
endoplasmic reticulum stress [13].
Although several lines of scientiﬁc data from in vitro
and in vivo studies supporting Ling Zhi’s various pharma-
cological activities have been extensively documented, the
pharmacokinetic study regarding its bioactive compounds
in human have not yet been reported. Therefore, the
purposes of this paper were to evaluate the pharmacokinetics
of ganoderic acids A and F and the inﬂuence of food
on their pharmacokinetics after an oral administration of
the water extract of fruiting bodies of MG2-strain Ling
Zhi (MG2FB-WE), produced by the Muang Ngai Special
Agricultural Project under the patronage of Her Majesty
Queen Sirikit, in healthy Thai male volunteers. This water
extract of Ling Zhi in granular formulation is being under
intensive investigation for its eﬃcacy in the treatment of
gynecologic and other cancers in the clinical trials conducted
by the Faculty of Medicine, Chiang Mai University (CMU),
Thailand.
2.MaterialsandMethods
2.1. Study Design. The study was a single-dose, open-label,
randomized, two-phase crossover study with at least a 2wk
washout period. This study was approved by the Human
Research Ethics Committee of the Faculty of Medicine,
CMU, and complied with the Declaration of Helsinki.
2.2. Subjects. Twelve healthy Thai male subjects, aged
between 18–40y whose body mass index were within the
normal range (18–25kg/m2), were enrolled into this study.
All subjects had to be considered healthy on the basis of
their medical history and physical examination. The results
of routine laboratory tests including complete blood count,
liver function test, blood urea nitrogen, and creatinine had
to be within normal limits. Subjects included in the study
were given both verbal and written information regarding
the nature and purpose of the study. Informed consent was
voluntarily obtained from each subject prior to participation
in the study. Exclusion criteria were subjects with known
hypersensitivity to Ling Zhi, known medical history of
neurological, pulmonary, kidney, liver, cardiovascular dis-
eases, or malignancy, recent cigarette smoking within the
previous 3 months, use of alcohol, substance abuse, any
Ling Zhi preparation, as well as other medications (except
acetaminophen) within the previous 1 month.
2.3. Dosage and Administration. Eligible subjects were
admitted to the Clinical Pharmacology Unit, Faculty of
Medicine, CMU, at 6:30 AM after an overnight fast of at
least 8h. Each subject was randomized to receive a single
oral dose of MG2FB-WE either under a fasting condition,
or immediately after a Melander type standard breakfast
(fed condition). The standard breakfast consists of 150mL
semiskimmed milk, 100mL orange juice, 1 hard-boiled egg,
2 pieces of whole wheat bread, 5g margarine, 20g orange
marmalade and 20g hard cheese [14]. The 3,000mg of
MG2FB-WE in granular formulation containing 1,417.80 ±
40.74μg/g of ganoderic acid A and 224.15 ± 8.02μg/g of
ganoderic acid F was dissolved in 200mL of warm water
before oral administration. All subjects were instructed to
remainuprightwithoutintakeofanyfoodorbeveragefor2h
after Ling Zhi administration. Water and lunch were served
at 2 and 4h after dosing, respectively. Serial blood samples
were collected at diﬀerent time points as described below.
After blood sample collection at 8h after dose, all subjects
were discharged from the Clinical Pharmacology Unit. After
a washout period of at least 2wk, the subjects were crossed
over to receive the same oral dose of Ling Zhi preparation
after an alternative (fasting or fed) condition. The blood
sample collection and other study conditions in the 2nd
study period were as same as the previous study period. An
identical meal and ﬂuid were served on both study days. All
subjectswereinstructedtoavoidconsumptionofLing Zhior
any Ling Zhi preparation throughout the study period.
2.4. Blood Sample Collection. Serial blood sample collections
(10mL each) were obtained before oral administration of
the Ling Zhi preparation, and at 5, 10, 15, 30, and 45min,
t h e na t1 ,1 . 5 ,2 ,2 . 5 ,3 ,3 . 5 ,4 ,5 ,6 ,a n d8h ,r e s p e c t i v e l y ,a f t e r
dosing for the determination of the plasma concentration of
ganoderic acids A and F. The blood samples were obtainedEvidence-Based Complementary and Alternative Medicine 3
from the forearm by venipuncture through an indwelling
intravenous catheter and collected into heparinized vacu-
tainers. The blood collecting tubes were centrifuged at
1,040g for 15min at 4◦C and the plasma was then separated
and frozen at −20◦C until analysis.
2.5. DeterminationofGanodericAcidsAandFConcentrations
2.5.1. Sample Preparation. The plasma sample extraction for
the quantitative determination of ganoderic acids A and
F was performed by using protein precipitation method.
Concisely, 250μL of each plasma sample was spiked with
25μL of internal standard (IS, 2.50ng/mL of cortisone 21-
acetate), and subsequently deproteinated by mixing with
500μL of 1% acetic acid in 50% methanol/acetonitrile and
then kept at room temperature for 20min. The proteins in
the plasma sample were separated by centrifuge at 18,620g
for 10min at room temperature. Thereafter, an aliquot of
the supernatant was removed and evaporated to dryness by
the concentrator at 60◦C for 1.5h. The residues were then
dissolved in 50μL of mobile phase and a 15μL of the sample
was injected into the LC-MS system. LC-MS chromatogram
of plasma containing ganoderic acids A and F and IS is
presented in Figure 2. Plasma concentration of ganoderic
acids A and F were determined by using a calibration curve
of the peak area ratios of each ganoderic acid and IS,
versus respective ganoderic acid concentrations with the use
of linear regression analysis (correlation coeﬃcient value
≥0.99).
2.5.2. LC-MS System and Conditions. All analyses were
performed using an Agilent 1100 series LC system coupled
with MSD single quadrupole mass spectrometer (Agilent
LC/MSD API-Electrospray) system. The sample were sep-
arated using a Zorbax SB-C18 analytical column (4.6 ×
150mm, 5μm) from Agilent technologies in a 20min run-
time. Solvent A consisted of 10mM of ammonium formate
(pH 4.00), whereas solvent B was acetonitrile. The mobile
phase was delivered in a constant ratio of solvent A:B
(40:60, v/v) at ﬂow rate of 1.0mL/min. The MS was
equipped with an electrospray ionization interface and
operated in positive ion mode in mass-to-charge radios of
499.40 and 555.30m/z for ganoderic acid A, 571.30 and
572.30m/z for ganoderic acid F and 403.20 and 441.20m/z
for IS. The gas temperature was 350◦C, drying gas 13L/min,
and nebulizer pressure 50psi.
2.6. Assay Validation. The assay validation was performed
following the US Food and Drug Administration guidance
for bioanalytical method validation [15]. The LLOQ value of
both ganoderic acids A and F under the LC-MS condition
used in this study was 0.50ng/mL. The percentages of
coeﬃcient of variation (% CV) at LLOQ concentration
of ganoderic acids A and F were 5.92% and 15.90%,
respectively, whereas the accuracy at this concentration were
113.50% and 114.95%, respectively. The mean % CV of
intradayprecisionofganodericacidsAandFwere3.48%and
3.62%, respectively, whereas, those of interday of ganoderic
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Figure 2:LC-MSchromatogramofplasmacontaining18.00ng/mL
of ganoderic acids A (GA, retention time = 5.298min) and F (GF,
retention time = 10.519min) as well as 2.50ng/mL of IS (retention
time = 9.110min).
acids A and F were 3.64% and 3.17%, respectively. Likewise,
the mean accuracy of intraday assay validation of ganoderic
acid A and F were 105.16% and 101.38%, respectively,
whereas those of interday of ganoderic acids A and F were
103.01% and 99.35%, respectively. The mean recovery of
ganoderic acids A and F including IS were 73.51%, 89.52%,
and 72.66%, respectively.
2.7. Data Analysis and Statistical Methods
2.7.1. Pharmacokinetic Parameters. The maximum plasma
concentration (Cmax, ng/mL) and time to reach maximum
concentration (Tmax, h) of ganoderic acids A and F were
evaluated directly by visual inspection of each subject’s
plasma concentration-time proﬁle. The area under the
concentration-time curve from administration to 8h and
to inﬁnity (AUC0–8 and AUC0–∞,n g ·h / m L )a sw e l la se l i m -
ination half-life (t1/2, h), were determined by non-com-
partmental analysis. The slope of the terminal log-linear
portion of the concentration-time proﬁle was determined by
least-squares regression analysis and used as the elimination
rate constant (Ke). The elimination t1/2 was calculated from
the ratio of 0.693/Ke. The AUC from time zero to the
last quantiﬁable point (AUC0–8) was calculated by using
the trapezoidal rule and the extrapolated AUC from time
t to inﬁnity (AUCt–∞) was determined as Ct/Ke .T o t a l
AUC was the sum of AUC0–8 +A U C 8–∞. The calculation
was performed by using the Topﬁt software version 2.0 for
personal computer.
2.7.2. Statistical Analysis. The pharmacokinetic parameters
were presented as mean ± standard deviation (SD). The
diﬀerences in the mean values of Cmax, Tmax, t1/2,A U C 0–8,
and AUC0–∞ between fasting and fed conditions were
analyzedbyusingpairedStudent’st-testandwereconsidered
statistically signiﬁcant if P<0.05.
3. Results
The demographic characteristics and means of clinical
laboratorydataof12subjectsenrolledinthestudyareshown4 Evidence-Based Complementary and Alternative Medicine
Table 1: The demographic characteristics and clinical laboratory data of 12 subjects enrolled in the study.
Parameters Mean ± SD Range Normal values
Age (y) 26.83 ±4.86 20–33
Weight (kg) 58.38 ±7.29 48.5–74.0
Height (m) 1.69 ±0.06 1.60–1.78
BMI (kg/m2)2 0 .51 ±1.97 18.25–23.36 18–25
Laboratory data
Hemoglobin (g/L) 145.50 ±6.49 130–157 130–180
Hematocrit (L/L) 0.45 ±0.02 0.43–0.48 0.40–0.54
WBC (×109/L) 7.93 ±1.83 5.6–11.0 4.4–11.0
Platelets on smear Adequate — Adequate
BUN (mg/dL) 13.17 ±1.95 10–17 8.4–21
Creatinine (mg/dL) 1.08 ±0.11 0.9–1.3 0.8–1.3
SGOT (U/L) 21.58 ±4.54 16–30 0–37
SGPT (U/L) 23.50 ±9.13 13–39 0–41
ALP (U/L) 47.50 ±11.02 30–64 53–128
Total bilirubin (mg/dL) 0.42 ±0.23 0.2–0.9 0.1–1.2
BMI: body mass index; WBC: white blood cell; BUN: blood urea nitrogen; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic
transaminase; ALP: alkaline phosphatase.
in Table 1. All subjects completed the study protocol. On the
basisofmedicalhistory,physicalexaminationandlaboratory
investigation, none of the subjects showed any evidence
of neurological, pulmonary, kidney, liver, or cardiovascular
diseases.
The mean plasma concentration-time curves of gan-
oderic acid A at various sampling times from 12 subjects
after a single oral administration of 3,000mg of MG2FB-
WE under a fasting or fed condition are presented in
Figure 3.ThatofganodericacidFunderafastingconditionis
presented in Figure 4. However, the mean plasma ganoderic
acid F concentration-time curve under a fed condition is not
shown due to insuﬃcient data for calculation since plasma
ganoderic acid F concentrations that are higher than the
LLOQ were detected only in 2 out of 12 subjects. In one
subject, the concentrations of 0.59 and 0.50ng/mL were
found at 2.50h and 3.00h after MG2FB-WE administration,
respectively, whereas the concentration of 0.56ng/mL was
found at 3.50h after dosing in another subject.
The pharmacokinetic parameters of ganoderic acids A
and F (Cmax, Tmax, t1/2,A U C 0–8,a n dA U C 0–∞) following
a single oral administration of 3,000mg of MG2FB-WE
under a fasting or fed condition are presented in Table 2.
Underafastingcondition,bothganodericacidsreachedtheir
Tmax at approximately 30min. Ganoderic acids A and F had
a very short elimination t1/2 of 37.20min and 28.80min,
respectively. Food signiﬁcantly decreased Cmax as well as
delayed Tmax and t1/2, but did not aﬀect the extent (AUC0–8
andAUC0–∞)ofganoderic acidA.However,sincetheplasma
ganoderic acid F concentrations at any time points under a
fed condition were below the LLOQ in most of the enrolled
subjects,thepharmacokineticparameterssuchasCmax,Tmax,
t1/2,A U C 0–8 including AUC0–∞ were not be determined and
thereforewerenotbestatisticallycomparedwiththoseunder
a fasting condition.
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Figure 3:MeanplasmaganodericacidAconcentration-timecurves
after a single oral dose of MG2FB-WE under a fasting or fed
condition.
4. Discussion
This is the ﬁrst report on the pharmacokinetic study of
ganoderic acids A and F after a single oral administration
of MG2FB-WE in healthy Thai male volunteers. Since the
study design of this pharmacokinetic study was similar to
that of bioequivalence testing, the minimum number of 12
subjects were enrolled in the study according to the guideline
on investigation of bioequivalence [16]. Additionally, a two-
phase crossover study was conducted in order to minimize
subject variability between fasting and fed conditions.
The MG2FB-WE used in our pharmacokinetic study
is currently under intensive investigation at the FacultyEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Mean plasma ganoderic acid F concentration-time curve
after a single oral dose of MG2FB-WE under a fasting condition
(mean plasma ganoderic acid F concentration-time curve under a
fed condition is not shown due to insuﬃcient data for calculation).
of Medicine, CMU, for its eﬃcacy in the treatment of
advanced gynecologic and other advanced-stage cancers
using a dosage of 3,000mg twice daily (6,000mg/day) for
3 months. This dosage was selected in accordance to the
study previously reported by Gao et al. [17] exhibiting that
the oral administration of 5,400mg/day of Ling Zhi extract
for 12wk signiﬁcantly enhances the immune responses
in patients with advanced-stage cancers. Indeed, MG2FB-
WE used in the ongoing clinical trials was prepared as
granular formulation dissolved in 200mL of warm water
before oral administration. This formulation has proved to
be easier and more acceptable for the cancer patients to
consume than other dosage forms, such as a single dose of
6 capsules (500mg/capsule) each time. Therefore, a single
dosage of 3,000mg of MG2FB-WE in granular formulation
wasinvestigatedinthepresentstudybasedonthedosageand
formulation used in the ongoing clinical trials mentioned
above. In addition, the granular formulation was considered
to be superior to other formulations (capsules and tablets) in
this pharmacokinetic study because the granules are readily
dissolved and absorbed without the necessity to evaluate
for its dissolution and disintegration proﬁles, which are the
major confounding factors during an absorptive phase.
The measurement of plasma ganoderic acids A and F
was performed by using the LC-MS method due to its rapid
(runtime of 20min), high speciﬁcity and sensitivity (LLOQ
of 0.50ng/mL) in comparison to longer runtime (runtime
of 60min) and lower sensitivity (LLOQ of 2.50μg/mL) by
HPLC-UV (252nm) technique in our preliminary experi-
ments. The validation of LC-MS assay demonstrated validity
in precision, accuracy as well as recovery following the US
FDA guidance, thus showing the suitability of this method
for analysis of ganoderic acids A and F in plasma samples.
According to plasma concentration-time curves under
a fasting condition, ganoderic acids A and F could be
detected in the plasma as early as 5–10min after an oral
administration and reached their Tmax at approximately
30min. Both ganoderic acids A and F had a very short
elimination t1/2 of 37.20min and 28.80min, respectively.
These ﬁndings are in agreement with the previously reported
pharmacokinetic parameters in animals that revealed rapid
absorption and elimination of G. lucidum triterpenes as
evidenced by a Tmax value range from 18–110min and
elimination t1/2 of 35–143min [18–20]. AUC of ganoderic
acids A and F were low in spite of large dose of Ling Zhi
preparation containing relatively high contents of ganoderic
acids A (4253.40μg) and F (642.75μg) was administered.
This data suggests low oral bioavailability of ganoderic acids
A and F, which was consistent to the bioavailability of
approximately 10% of ganoderic acid A reported in previous
studies [18]. Since the rate of drug absorption is almost
always directly proportional to the extent of absorption, we
thereforepostulatedthattherelativelyloworalbioavailability
of ganoderic acids A and F could probably not result from
the poor absorption from gastrointestinal tract because their
absorption appeared to be very rapid. However, this poor
oral bioavailability might be due to their extensive hepatic
ﬁrst-pass metabolism coupled with partial conversion of
some triterpenes to their metabolites by intestinal bacteria
as reported in rat feces, but not in plasma and urine [20].
Further studies should be investigated to identify the exact
mechanisms involving in this low oral bioavailability.
It is well known that food may positively or nega-
tively aﬀect the rate and/or extent of the bioavailability
of various drugs [21–23]. This study revealed that food
caused a signiﬁcant decrease in Cmax and rate of absorption
(Tmax) of ganoderic acid A, but not the extent (AUC)
of absorption. Since it is established that most drugs are
ordinarily absorbed from the small intestine and delayed
gastricemptyingwilldelayabsorptionofthosedrugsthatare
absorbed predominantly from the small intestine [21, 23],
we postulated that food aﬀected the rate but not the extent
of ganoderic acid A absorption through slowing of gastric
emptying. Indeed, many dietary factors, such as solid food,
high-fat content, and high osmolarity, have been found to
delay gastric emptying [21–23]. Nonetheless, concomitant
food administration also signiﬁcantly prolonged the t1/2 of
ganoderic acid A. This ﬁnding presumably resulted from
the delayed ganoderic acid A absorption due to prolonged
gastric emptying by food, yielding sustained plasma levels
and distorted the terminal t1/2 under a fed condition.
The absorption of ganoderic acid F was probably aﬀected
by food in the same manner as that of ganoderic acid A.
Since the concentrations of ganoderic acid F were already
low under a fasting condition, the eﬀect of food would
then impede the absorption to the point that its plasma
concentrations were lower than the LLOQ. Its pharmacoki-
netic parameters, likewise, could not be assessed. Owing to
the fact that food intake generally impairs the rate and/or
extent of ganoderic acids and perhaps other triterpenes, we
recommend that Ling Zhi preparations should be taken on
an empty stomach whenever possible.
Several in vitro studies have demonstrated that cytotox-
icity against various human cancer cell lines expressed as
IC50 valuesareintherangeof9.47–26.50μM(approximately6 Evidence-Based Complementary and Alternative Medicine
Table 2: Pharmacokinetic parameters of ganoderic acids A and F after a single oral administration of MG2FB-WE under a fasting or fed
condition.†
Parameters Ganoderic acid A Ganoderic acid F
Fasting condition Fed condition Fasting condition Fed condition
Cmax (ng/mL) 10.99 ±4.02∗∗ 3.84 ±1.56 2.57 ±0.91 ND
Tmax (h) 0.54 ± 0.18∗ 1.67 ±0.88 0.52 ±0.13 ND
t1/2 (h) 0.62 ± 0.17∗ 1.34 ±0.65 0.48 ±0.22 ND
AUC0–8 (ng·h/mL) 9.58 ±4.08 8.75 ±5.32 1.81 ±0.76 ND
AUC0–∞ (ng·h/mL) 10.53 ±4.32 11.02 ±5.54 2.42 ±0.93 ND
†Data represents mean ± SD.
∗P<0.01, ∗∗P<0.001 denote statistically signiﬁcant as compared to a fed condition according to paired Student’s t-test.
ND: cannot be determined because the plasma ganoderic acid F concentrations at any time points were below the LLOQ in most of the enrolled subjects.
4,900–13,700ng/mL) for ganoderic acid A [11] and 9.62–
19.50μM (approximately 5,500–11,000ng/mL) for gan-
oderic acid F [11, 13]. These targeted concentrations are
much higher than the mean Cmax of 10.99 ± 4.02ng/mL
for ganoderic acid A and 2.57 ± 0.91ng/mL for ganoderic
acid F found in this study. Therefore, it is unlikely to
achieve cytotoxic eﬀects in vivo although a relatively high-
dose or multiple-dosage regimen of Ling Zhi extract is used.
However, Ling Zhi is well documented to contain over 150
types of triterpenes [2, 3], and many of them have been
demonstrated to possess direct anticancer activity through
diﬀerent mechanisms of action for example, induction of
cell cycle arrest and apoptosis [24, 25], inhibition of pro-
liferation, migration, invasion, metastasis, and angiogenesis
of carcinoma cell lines [10, 12, 13, 26]. Therefore, in vivo
anti-cancer activity might be exerted via synergistic eﬀects
among these triterpenes and with other biologically active
compounds such as immunomodulatory protein, Ling Zhi-
8[ 27, 28]. Additionally, polysaccharide fractions might
also play some additional beneﬁts through activation of an
immune response against cancer [29, 30].
The major limitation of present study was the lim-
ited ability of the LC-MS technique to measure very low
levels of ganoderic acid F in plasma samples, especially
under a fed condition, because its plasma concentrations
at any time points were lower than the LLOQ value of
an analytical method, being unable to establish individual
plasma concentration-time data and hence calculation for
pharmacokinetic parameters. Therefore, a more sensitive
analytical method (such as LC-MS/MS) or study using a
Ling Zhi preparations containing high content of ganoderic
acid F are suggested for the determination of human plasma
ganoderic acid F and other triterpenes concentrations in
future studies.
5. Conclusion
The pharmacokinetic proﬁle of both ganoderic acids under a
fastingconditionwascharacterizedbyrapidabsorptionfrom
the gastrointestinal tract (Tmax at approximately 30min) and
a short elimination half-life (<40min). Food signiﬁcantly
decreasedCmax anddelayedTmax,butdidnotaﬀecttheextent
(AUC0–8 and AUC0–∞) of ganoderic acid A absorption.
However, concomitant food intake markedly impeded both
rate and extent of ganoderic acid F absorption.
Abbreviations
AUC0–∞: Area under the concentration-time curve from
administration to 8h
AUC0–∞: Area under the concentration-time curve from
administration and extrapolation to inﬁnity
Cmax: Maximum plasma concentration
Ct: Concentration at time t
Ke: Elimination rate constant
t1/2: Half-life
Tmax: Time to reach maximum concentration.
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